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The personality domains of extraversion and neuroticism are regarded as being stable individual psychological
characteristics, yet it remains unclear whether they are associated with chronic disease over an extended period of
time. In a randomized controlled trial of smoking cessation nested within the original prospective Whitehall Study
(1967–2012), the Eysenck Personality Questionnaire was administered to 832 male self-declared smokers who
had undergone a medical examination during which their levels of extraversion and neuroticism were quantified.
In the 42-year follow-up period, there were 781 deaths. In analyses in which participants from both trial arms
were pooled, there was little evidence of a robust relation of either personality domain with death from all causes,
coronary heart disease, stroke, respiratory disease, or cancer in any of our analyses.We therefore found no support
for a role of either extraversion or neuroticism as determinants of long-term mortality risk.
cancer; cohort study; coronary heart disease; extraversion; mortality; neuroticism; personality type; respiratory
disease; stroke
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The notion that an individual’s personality may have an
impact on his or her health can be traced back to ancient writ-
ings (1). Over the past 2 decades, it has been suggested in a
series of empirical reports that people with low levels of neu-
roticism and high levels of agreeableness, extraversion, and
conscientiousness may experience a lower risk of total mor-
tality (2), although these are not universal observations (3).
As the cohort studies on which these observations were
based have matured, it has become possible for investiga-
tors to explore the association of personality traits with spe-
ciﬁc chronic disease outcomes of public health importance,
such as cardiovascular disease and cancer. The modest ev-
idence base to date suggests that, for cardiovascular disease
endpoints—in particular coronary heart disease—neuroticism
is, with rare exception (4), typically associated with an ele-
vated risk (5). On the other hand, in large-scale studies (6)
and meta-analyses (7), there has been no link shown between
this personality domain and risk of all cancers combined. For
extraversion, a recent aggregation of effect estimates across
previously unpublished studies indicated no association with
coronary heart disease but a positive relation with stroke (5).
Again, the best evidence does not imply any extraversion-
malignancy relationship (6, 7). Plausible mechanisms advanced
for positive results with respect to cardiovascular disease out-
comes, where they exist, include a more favorable risk factor
proﬁle—a lower prevalence of smoking (8), harmful level of
alcohol intake (9), and existing disease (clinical and subclini-
cal) (10) and lower levels of weight (11), blood pressure, and
blood lipids—in the lower risk personality groups.
There has been some suggestion that certain personality
types are more consistently associated with chronic disease
risk in studies with a shorter duration of mortality surveil-
lance (12, 13), with the strength of these relationships dimin-
ished or lost when a longer period of follow-up is utilized
(4, 14). Rather than supporting the stability of personality
as a risk factor for mortality (15), this ﬁnding is consistent
with a reverse causality explanation, which posits that hidden
or unmeasured disease may unfavorably inﬂuence self-rated
436 Am J Epidemiol. 2016;184(6):436–441
American Journal of Epidemiology
© The Author 2016. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium,
provided the original work is properly cited.
Vol. 184, No. 6
DOI: 10.1093/aje/kwv454
Advance Access publication:
September 1, 2016
personality disposition (16) and simultaneously raise short-
term mortality risk. Studies with several decades of mortality
surveillance have the advantage of minimizing the inﬂuence
of reverse causality because the proportion of persons with
existing disease at study entry relative to chronic disease
events accumulation decreases over time (17). Given the rel-
ative recency of research activity in personality epidemiol-
ogy, however, such studies are rare.
A further consideration when interpreting the personality
and health literature is the inﬂuence of publication bias,
which is the notion that positive results have a better chance
of being published. Thus, in an individual meta-analysis of
unpublished raw data, the association between personality
type and survival (3) was weaker than that seen in the pub-
lished literature. Similar observations have been made in
the context of other psychological predictors of health,
such as job strain and coronary heart disease (18).
Against this background of inconsistent ﬁndings, limited ev-
idence, potential publication bias, and the problem of reverse
causality, we analyzed data from a smoking cessation trial
nested within the original Whitehall Study. With surviving
study members now entering their ﬁfth decade of follow-up
after personality measurement, this study is well placed to ad-
dress some of these methodological considerations.
METHODS
The original Whitehall Study is a prospective cohort study
with ongoing mortality surveillance (19, 20). Between 1967
and 1970, baseline datawere collected on 19,019male civil ser-
vice (government) employees who were based in London,
UnitedKingdom, andwere 40–69 years of age. This represented
a 77% response proportion from the target population. Data col-
lection involved the completion of a study questionnaire and
participation in a medical examination, both of which have
been described in detail previously (19). In brief, during the
medical examination, blood pressure (21), height, weight, pul-
monary function (assessed using forced expiratory volume in
1 second) (22), and, after an overnight fast, plasma cholesterol
(23) were measured using standard protocols of the period.
Bodymass indexwas computed using the usual formula (weight
(kg)/height (m)2) (24). The questionnaire included enquiries
about employment grade (an indicator of socioeconomic status)
(25), smoking habits (26), physical activity level (inactivity was
deﬁned as inactive leisure activity or no travel activity) (27), and
existing disease (1 or more of the following: electrocardio-
graphic evidence of ischemia, self-reported dyspnea, intermit-
tent claudication, unexplained weight loss, bronchitis, use of
blood pressure–lowering medication, or being under the care
of a physician because of heart trouble or hypertension).
The data on personality traits were collected from a sub-
group of male cigarette smokers who participated in a trial
of smoking cessation, respiratory health, and mortality that
was nested within the original cohort study, which served
as a screening study (see Web Figure 1, available at http://
aje.oxfordjournals.org/, for derivation of trial sample). As
outlined elsewhere (28–31), 1,500 cigarette smokers with ad-
ditional risk factors for cardiovascular disease—based on an
early version of the Framingham index (32)—were targeted
for recruitment into a randomized controlled trial of smoking
cessation in which advice about quitting was dispensed by a
physician. In an era in which the health effects of cigarette
smoking were not fully understood, the usual care group re-
ceived no cessation advice. In addition to the baseline med-
ical examination that was carried out as part of the cohort
study, detailed respiratory health measurements (lung func-
tion, self-reported phlegm and dyspnea, angina, etc.) were
taken 1 and 3 years after the initial intervention.
Eysenck Personality Questionnaire
Oneyear into the trial, presumably with the aim of examining
whether personality traits were associated with smoking cessa-
tion, interviewers administered the 12-item Eysenck Personality
Questionnaire (33) to 846 of the 1,204 attending men. Six items
were used to quantify neuroticism, including, “Are you fre-
quently ‘lost in thought’ even when supposed to be taking
part in a conversation?” and an additional 6 items were used
to assess extraversion, including, “Are you happiest when you
get involved in some project that calls for rapid action?” The in-
terviewers allocated 1 point for each positive response, −1
points for each negative response, and no points for answers
that could not be clearly classiﬁed as either a positive or negative
response. The possible scores on either factor therefore ranged
from 6 to −6, with a higher score indicating a higher level in
each personality domain. This version of the Eysenck Person-
ality Questionnaire has a long research pedigree and has been
incorporated into longer, contemporary neuroticism and extra-
version scales. Abbreviated versions of the Eysenck Personal-
ity Questionnaire had high correlation coefﬁcients with full
versions of the questionnaire for both neuroticism (0.88) and
extraversion (0.90) (34). There is also no apparent relationship
between the 2 personality types (r =−0.05) (33), an observa-
tion that was also made in the present sample (r =−0.03).
Mortality ascertainment
Using the procedures of UK National Health Service Cen-
tral Registry, we traced the vital status of 99% of the men to
whom the personality questionnaire was administered. Based
on the underlying cause, deaths were classiﬁed as resulting
from coronary heart disease (International Classiﬁcation of
Disease Eighth or Ninth Revision codes 410–414 and
Tenth Revision codes I20–I25), stroke (Eighth or Ninth Re-
vision codes 430–438; Tenth Revision codes I60–I69), respi-
ratory illness (Eighth or Ninth Revision codes 460–519;
Tenth Revision codes J00–J99), or cancer (Eighth or Ninth
Revision codes 140–209; Tenth Revision codes C00–C97).
Statistical analyses
In total, we had full data on personality type, mortality, and
covariates for 832 of the 846 trial participants, and this rep-
resented our analytical sample. Neuroticism (≤−4, −3 to 0,
or ≥1) and extraversion (≤−1, 0 to 2, or ≥3) scores were
grouped into tertiles, with the lowest tertile serving as the ref-
erent. Using an approach we have taken elsewhere (35, 36),
with no strong evidence that trial arm had a modifying effect
on the personality type–mortality relationship, we pooled
data, and effect estimates were adjusted for arm allocation.
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Hazard ratios with accompanying 95% conﬁdence intervals
were computed using Cox’s proportional hazards regression
model (37) with calendar time as the time scale. Participants
were censored at date at death, date at loss to follow-up, or
end of follow-up (September 30, 2012), whichever came
ﬁrst. Hazard ratios were initially adjusted for age and thereaf-
ter for a series of covariates: employment grade, smoking
habit (number of cigarettes smoked per day at the start of
the trial and smoking status at the time of completion of
the personality questionnaire after 1 year), physical activity
level, body mass index, systolic blood pressure, plasma cho-
lesterol, height-adjusted forced expiratory volume in 1 sec-
ond, and disease at study entry. We performed separate
signiﬁcance tests for linear trend and quadratic-shaped asso-
ciation across the neuroticism and extraversion tertiles.
RESULTS
In the Web Tables 1 and 2, we show levels of covariates ac-
cording to categories of personality type. Higher extraversion
scores were associated with a slightly higher body mass index,
but there were no associations with any of the other covariates.
For neuroticism, ﬁndings were mixed: Somewhat lower levels
of plasma cholesterol and systolic blood pressurewere apparent
in men with high neuroticism scores; conversely, disease at
study entry was 20% more common in this group. In Table
1, we show the relationship between neuroticism and a range
of mortality outcomes. In the 42-year follow-up period, there
were 781 deaths (219 from cancer, 215 from coronary heart
disease, 139 from respiratory disease, 66 from stroke, and
142 from other causes). There was little evidence that neurot-
icism was linked to death from all causes, stroke, respiratory
disease, or cancer. Thus, in comparing the risk among partic-
ipants in highest tertile of neuroticism with that among partic-
ipants in the lowest tertile over the 42-year follow-up period,
hazard ratios ranged between 0.78 (95% conﬁdence interval:
0.57, 1.09) for stroke mortality and 1.60 (95% conﬁdence in-
terval: 0.69, 3.69) for respiratory disease mortality. When cor-
onary heart disease was the endpoint of interest, in univariate
analyses, there was a suggestion of a shallow U-shaped rela-
tionship with neuroticism such that the lowest risk was seen
in men with moderate values, whereas those with low or
Table 1. Hazard Ratios for the Associations of Neuroticism With Total Mortality, Coronary Heart Disease, Stroke, Respiratory Disease, and
Cancer Among Study Participants (n = 832), 42-Year Mortality Surveillance in the Original Whitehall Smoking Cessation Trial, 1967–2012
Cause of Mortality and
Adjustment
No. of
Deaths
Neuroticism Tertiles
P for Linear
Relation
P for Quadratic
RelationLow (n = 311) Medium (n = 293) High (n = 228)
HR 95% CI HR 95% CI HR 95% CI
Total mortality
Age-adjusted 781 1.00 Referent 0.94 0.80, 1.11 1.03 0.86, 1.23 0.84 0.30
Multiply adjusteda 781 1.00 Referent 1.02 0.86, 1.21 1.08 0.90, 1.30 0.43 0.79
Multiply adjusted (20-year
follow-up)a
372 1.00 Referent 1.00 0.77, 1.28 1.24 0.95, 1.61 0.13 0.33
Coronary heart disease
mortality
Age-adjusted 215 1.00 Referent 0.78 0.57, 1.09 1.14 0.82, 1.58 0.56 0.04
Multiply adjusteda 215 1.00 Referent 0.88 0.63, 1.23 1.23 0.87, 1.72 0.30 0.12
Multiply adjusted (20-year
follow-up)a
129 1.00 Referent 0.95 0.62, 1.46 1.23 0.79, 1.90 0.40 0.42
Stroke mortality
Age-adjusted 66 1.00 Referent 0.95 0.54, 1.65 0.91 0.48, 1.70 0.75 0.98
Multiply adjustedb 66 1.00 Referent 1.27 0.70, 2.30 1.15 0.59, 2.22 0.63 0.54
Respiratory disease mortality
Age-adjusted 139 1.00 Referent 1.14 0.78, 1.68 1.03 0.67, 1.61 0.83 0.50
Multiply adjusteda 139 1.00 Referent 1.19 0.79, 1.80 1.05 0.66, 1.66 0.80 0.41
Multiply adjusted (20-year
follow-up)a
41 1.00 Referent 1.52 0.66, 3.47 1.60 0.69, 3.69 0.28 0.60
Cancer mortality 1.00 Referent 0.96 0.71, 1.31 0.98 0.70, 1.38 0.88 0.84
Age-adjusted 219 1.00 Referent 0.96 0.71, 1.31 0.98 0.70, 1.38 0.88 0.84
Multiply adjusteda 219 1.00 Referent 0.97 0.70, 1.34 0.99 0.69, 1.41 0.93 0.86
Multiply adjusted (20-year
follow-up)a
113 1.00 Referent 0.90 0.57, 1.42 1.12 0.69, 1.81 0.70 0.42
Abbreviations: CI, confidence interval; HR, hazard ratio.
a Multiple adjustment is adjustment for age, employment grade, number of cigarettes smoked per day at the start of the trial, smoking habit at
administration of the personality questionnaire (year 1 of trial), physical activity level, arm of smoking trial, body mass index, systolic blood
pressure, plasma cholesterol level, height-adjusted forced expiratory volume in 1 second, and disease at study entry.
b There were only 24 stroke deaths in the first 20 years of follow-up, which was insufficient for subgroup analyses.
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high scores had slightly higher rates (for quadratic association,
P = 0.04); however, this became less evident after multiple ad-
justment for covariates.When extraversionwas the exposure of
interest (Table 2), U-shaped relationships were again apparent
with total, coronary heart disease, stroke, and respiratory dis-
ease mortality, although statistical signiﬁcance at conventional
levels was infrequent. Adjustment for several covariates, in-
cluding health behaviors and biological risk indicators, did
not markedly change this pattern of association.
When we examined the personality–mortality associations
in the earlier (20-year) stages of follow-up, there was no sug-
gestion that the strength of the relationship was greater than in
the full (42-year) follow-up. This was conﬁrmed statistically
using a test of interaction of all personality–mortality associ-
ations according to duration of follow-up (all P ≥ 0.08).
DISCUSSION
In the present study in which we utilized data from a smok-
ing cessation trial in cohort study analyses, there was some
evidence that opposing ends of the extraversion spectrum
were associated with a modestly elevated risk of coronary
heart disease and respiratory disease mortality. That our
point estimates did not attain statistical signiﬁcance in any
analyses and were of modest magnitude, however, generally
points to a null set of results for both extraversion and neurot-
icism in relation to a range of mortality outcomes. When we
examined the personality–mortality associations in the earlier
stages of follow-up, the strength of the relationship was no
greater than in the full follow-up, which suggests little sup-
port for reverse causation.
Comparison with other studies
Our ﬁnding of no clear relationship between total mortality
and either personality dimension is supported by a recent
meta-analysis on this topic in which the authors aggregated
individual-level data from 7 prospective studies (3). In another
individual participant meta-analysis of hitherto unpublished
studies which featured the 5 major personality types, higher
Table 2. Hazard Ratios for the Associations of Extraversion With Total Mortality, Coronary Heart Disease, Stroke, Respiratory Disease, and
Cancer Among Study Participants (n = 832), 42-Year Mortality Surveillance in the Original Whitehall Smoking Cessation Trial, 1967–2012
Cause of Mortality and
Adjustment
No. of
Deaths
Extraversion Tertiles
P for Linear
Relation
P for Quadratic
RelationLow (n = 206) Medium (n = 376) High (n = 250)
HR 95% CI HR 95% CI HR 95% CI
Total mortality
Age-adjusted 781 1.00 Referent 0.86 0.72, 1.02 0.95 0.79, 1.16 0.72 0.07
Multiply adjusteda 781 1.00 Referent 0.89 0.74, 1.07 0.94 0.77, 1.14 0.60 0.24
Multiply adjusted
(20-year follow-up)a
372 1.00 Referent 0.87 0.67, 1.12 1.04 0.79, 1.36 0.72 0.14
Coronary heart disease
mortality
Age-adjusted 215 1.00 Referent 0.68 0.49, 0.95 1.00 0.71, 1.41 0.83 0.006
Multiply adjusteda 215 1.00 Referent 0.71 0.50, 1.00 0.99 0.69, 1.40 0.90 0.02
Multiply adjusted
(20-year follow-up)a
129 1.00 Referent 0.71 0.46, 1.10 0.98 0.63, 1.54 0.95 0.07
Stroke mortality
Age-adjusted 66 1.00 Referent 0.74 0.39, 1.38 0.97 0.51, 1.87 0.98 0.26
Multiply adjustedb 66 1.00 Referent 0.76 0.41, 1.42 1.00 0.52, 1.92 0.93 0.29
Respiratory disease
mortality
Age-adjusted 139 1.00 Referent 0.78 0.51, 1.19 1.08 0.69, 1.68 0.61 0.09
Multiply adjusteda 139 1.00 Referent 0.86 0.55, 1.36 1.13 0.71, 1.80 0.49 0.25
Multiply adjusted
(20-year follow-up)a
41 1.00 Referent 0.52 0.24, 1.15 0.90 0.41, 1.99 0.85 0.08
Cancer mortality
Age-adjusted 219 1.00 Referent 1.16 0.82, 1.62 0.94 0.64, 1.39 0.96 0.20
Multiply adjusteda 219 1.00 Referent 1.12 0.79, 1.58 0.89 0.60, 1.32 0.47 0.22
Multiply adjusted
(20-year follow-up)a
113 1.00 Referent 1.10 0.68, 1.79 1.11 0.65, 1.87 0.73 0.80
Abbreviations: CI, confidence interval; HR, hazard ratio.
a Multiple adjustment is adjustment for age, employment grade, number of cigarettes smoked per day at the start of the trial, smoking habit at
administration of the personality questionnaire (year 1 of trial), physical activity level, arm of smoking trial, bodymass index, systolic blood pressure,
plasma cholesterol level, height-adjusted forced expiratory volume in 1 second, and disease at study entry.
b There were only 24 stroke deaths in the first 20 years of follow-up, which was insufficient for subgroup analyses.
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levels of neuroticism were related to coronary heart disease
only, and higher levels of extraversion were associated with
stroke only (5). Elsewhere, in accordancewith our own ﬁndings,
investigators in some studies have found little of evidence of a
relationship of either extraversion or neuroticism with coronary
heart disease (4, 38), stroke (14, 38), or cancer (6).
Study strengths and limitations
Although our study has important strengths—the unusu-
ally long duration of follow-up and the high proportion of
deaths—it is not without its limitations. We quantiﬁed only
2 of the “big 5” personality types, so it is possible that asso-
ciations with our chronic disease endpoints may have been
evident with the remaining types. There was essentially no
correlation between our 2 personality domains, which sup-
ports the notion that neuroticism and extraversion are separate
psychological entities, but this does not rule out the possibil-
ity of misclassiﬁcation of these phenotypes. The fact that this
was a study of smokers—at least at trial induction before
some members stopped smoking—means that, in principle,
there should be no variation in the habit across personality
groupings besides possible differences in the numbers of cig-
arettes smoked per day. Personality was, however, quantiﬁed
1 year into the trial after some men had quit (see Web Fig-
ure 1), so there were in fact individual differences in the
habit. We therefore adjusted our hazard ratios for the number
of cigarettes usually smoked at baseline, as well as for smok-
ing status at year 1. We sampled male government workers
who, in addition to being smokers, were otherwise classiﬁed
as being at high risk cardiovascular disease, so the extent to
which our ﬁndings are generalizable to women, lower risk
populations, and a wider social strata is unclear. However,
given that we explored risk factor–disease associations rather
than simply risk factor or disease prevalence or incidence, we
see no strong rationale for such a lack of external validity.
This has recently been conﬁrmed in comparative analyses
of the original Whitehall II Study relative to general
population-based cohort studies (39). Although the most fa-
vorable levels of risk factor prevalence and disease incidence
were apparent in the Whitehall II Study (the “healthy worker
effect”), risk factor–disease associations were essentially the
same, and often identical, across studies. This is as expected
because the inﬂuence of causal factors should not vary by
population structure. Similarly, we have no reason to think
that we cannot apply the results from the Whitehall Study
to other studies in this ﬁeld. In conclusion, in the present
study of men, there was little evidence of a robust association
of either neuroticism or extraversion with a range of cause-
speciﬁc mortality outcomes accumulated over an extended
period of follow-up.
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